Sanara MedTech Inc.
NASDAQ:SMTI · NASDAQ Capital Market
+$0.73 today
Vol 0.13M · Avg 0.06M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SMTI · Revenue to Net Income
Key Ratios
Analysis
$107.5M of revenue converted into -$33.6M of net income for the selected period. Gross margin is 91.2% and net margin is -31.9%, showing how much revenue survives after costs and taxes. EPS is $-3.90, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $103.1M +19.0% | $86.7M +33.4% | $65.0M +41.8% | $45.8M +89.9% | $24.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $10.2M +25.1% | $8.1M +3.7% | $7.9M +23.5% | $6.4M +175.2% | $2.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $92.9M +18.3% | $78.5M +37.4% | $57.1M +44.7% | $39.5M +80.8% | $21.8M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 90.1% -0.5pp | 90.6% +2.7pp | 87.9% +1.8pp | 86.1% -4.3pp | 90.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $5.1M -11.1% | $5.7M +38.0% | $4.1M +22.7% | $3.4M +502.7% | $558.7K | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $78.7M +2.8% | $76.6M +34.3% | $57.0M +24.0% | $46.0M +63.9% | $28.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $83.8M -1.7% | $85.2M +38.9% | $61.4M +18.0% | $52.0M +78.0% | $29.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.7M -45.9% | $4.9M +34.0% | $3.7M +55.0% | $2.4M +207.2% | $771.9K | $374.2M | $1.2B | $631.8M |
| EBITDA | $9.0M +585.3% | -$1.9M -543.5% | -$289.1K +97.5% | -$11.6M -60.2% | -$7.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 8.8% +10.9pp | -2.1% -1.7pp | -0.4% +24.8pp | -25.2% +4.7pp | -29.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | $9.1M +236.2% | -$6.7M -59.3% | -$4.2M +66.3% | -$12.5M -69.7% | -$7.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 8.9% +16.6pp | -7.7% -1.3pp | -6.5% +20.8pp | -27.3% +3.2pp | -30.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.7K -83.3% | $22.0K | $0 -100.0% | $284.7K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $6.8M +116.1% | $3.1M +557.5% | $475.8K +67.1% | $284.7K +39948.7% | $711 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$9.5M -198.4% | -$3.2M -1322.2% | -$224.7K +84.2% | -$1.4M -129.9% | -$617.6K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$393.1K +96.0% | -$9.9M -123.2% | -$4.4M +68.1% | -$13.9M -74.3% | -$8.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -0.4% +11.1pp | -11.4% -4.6pp | -6.8% +23.6pp | -30.4% +2.7pp | -33.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 +100.0% | -$5.8M | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$37.6M -288.7% | -$9.7M -124.6% | -$4.3M +45.8% | -$7.9M -0.2% | -$7.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | -36.4% -25.3pp | -11.2% -4.5pp | -6.6% +10.7pp | -17.3% +15.5pp | -32.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 -282.5% | -$1 -119.2% | -$1 +48.0% | -$1 +7.4% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 -282.5% | -$1 -119.2% | -$1 +48.0% | -$1 +7.4% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $8.6M +1.6% | $8.5M +2.5% | $8.3M +4.7% | $7.9M +7.7% | $7.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $8.6M +1.6% | $8.5M +2.5% | $8.3M +4.7% | $7.9M +7.7% | $7.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Viemed Healthcare, Inc.
NASDAQ:VMD
$406.95M
TruBridge, Inc.
NASDAQ:TBRG
$391.70M
NeoGenomics, Inc.
NASDAQ:NEO
$289.47M
Sight Sciences, Inc.
NASDAQ:SGHT
$280.21M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$267.86M
LifeMD, Inc.
NASDAQ:LFMD
$229.96M
Owens & Minor, Inc.
OMI
$207.07M
High Tide Inc.
NASDAQ:HITI
$203.87M
Stereotaxis, Inc.
AMEX:STXS
$178.37M
Exagen Inc.
NASDAQ:XGN
$105.34M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SMTI generate?
Sanara MedTech Inc. (SMTI) reported $103.12M of revenue in fiscal 2025.
Is SMTI profitable?
Sanara MedTech Inc. (SMTI) reported -$37,562,606.00 of net income, with a net margin of -36.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.